A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

• Status: RECRUITING
• Trial end date: 2028-08-01

Summary

This is a global, multicenter, randomized, open-label, Phase III confirmatory study to investigate the efficacy and safety of Lisaftoclax (APG-2575) in combination with Acalabrutinib in patients with newly diagnosed CLL/SLL.

• Phase: PHASE3

Details

• Lead Sponsor: Ascentage Pharma Group Inc.
• Treatments: acalabrutinib; Chlorambucil; fludarabine; Lisaftoclax; Rituximab